Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase III study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial

被引：0

作者：

Abou-Alfa, G. K. ^{[1
]}

Borbath, I. ^{[2
]}

Clarke, S. J. ^{[3
]}

Hitre, E. ^{[4
]}

Louvet, C. ^{[5
]}

Macarulla, T. ^{[6
]}

Oh, D-Y. ^{[7
]}

Spratlin, J. L. ^{[8
]}

Valle, J. W. ^{[9
]}

Weiss, K. H. ^{[10
]}

Berman, C. ^{[11
]}

Howland, M. ^{[12
]}

Ye, Y. ^{[13
]}

Cho, T. ^{[14
]}

Moran, S. ^{[11
]}

Javle, M. M. ^{[15
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA

[2] Clin Univ St Luc Bruxelles, HepatoGastroenterol & Digest Oncol, Brussels, Belgium

[3] Univ Sydney, Med Oncol, Sydney, NSW, Australia

[4] Natl Inst Oncol, Med Oncol, Budapest, Hungary

[5] Inst Mutualiste Montsouris, Med Oncol, Paris, France

[6] Hosp Valle De Hebron, Med Oncol, Barcelona, Spain

[7] Seoul Natl Univ Hosp, Med Oncol, Seoul, South Korea

[8] Alberta Hlth Serv, Med Oncol, Edmonton, AB, Canada

[9] Univ Manchester, Med Oncol, Christie, Manchester, Lancs, England

[10] Univ Hosp Heidelberg, Transplant Hepatol, Heidelberg, Germany

[11] QED Therapeut Inc, Clin Dev, San Francisco, CA USA

[12] QED Therapeut Inc, Clin Sci, San Francisco, CA USA

[13] QED Therapeut Inc, Biostat, San Francisco, CA USA

[14] QED Therapeut Inc, Clin Operat, San Francisco, CA USA

[15] Univ Texas MD Anderson Canc Ctr, Med Oncol, Houston, TX 77030 USA

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

832TiP

引用

页数：2

共 50 条

[41] Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
Rugo, Hope S.
Umanzor, Gerardo A.
Barrios, Francisco J.
Vasallo, Rosa H.
Chivalan, Marco A.
Bejarano, Suyapa
Ramirez, Julio R.
Fein, Luis
Kowalyszyn, Ruben D.
Kramer, E. Douglas
Wang, Hui
Kwan, Min-Fun R.
Cutler, David L.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (01) : 65 - +
[42] Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium
Lorusso, V
Crucitta, E
Silvestris, N
Rosati, G
Manzione, L
De Lena, M
ONCOLOGY REPORTS, 2005, 13 (02) : 283 - 287
[43] A multicenter, open-label, first-in-human study of TYRA-200 in advanced intrahepatic cholangiocarcinoma and other solid tumors with activating FGFR2 gene alterations (SURF201).
Rodon Ahnert, Jordi
Roychowdhury, Sameek
Ellis, Haley
Blanco, Fernando F.
Burn, Timothy
Davis, Jennifer Michelle
Balcer, Alex
Zalutskaya, Alena
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS646 - TPS646
[44] A pilot, open-label phase II study of sorafenib combined with cisplatin plus gemcitabine for the treatment of patients with advanced renal collecting duct carcinoma
Shang, Xi Nan
Cui, Chuan Liang
Chi, Zhihong
Si, Lu
Li, Si Ming
Mao, Li Li
Lian, Bin
Tang, Bi Xia
Wang, Xuan
Kong, Yan
Xie, Xiaodong
Zhou, Fang-Jian
Yuan, Jian-Iln
Wei, Qiang
Guo, Jun
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[45] Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma Including FGFR2 fusion or rearrangement: Updated overall survival from an open-label, single-arm, multicenter Phase II study
Shi, Guoming
Huang, Xiaoyong
Wen, Tianfu
Song, Tianqiang
Kuang, Ming
Mou, Haibo
Bao, Lequn
Zhao, Haitao
Zhao, Hong
Feng, Xielin
Zhang, Bixiang
Peng, Tao
Zhang, Yubao
Li, Xiangcheng
Yu, Hongsheng
Cao, Yu
Luo, Yang
Chen, Ye
Chen, Mingxia
Fan, Jia
Zhou, Jian
CANCER RESEARCH, 2023, 83 (08)
[46] Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: results from a Phase III randomized, open-label, multicenter trial
Motzer, R.
Nosov, D.
Eisen, T.
Bondarenko, I.
Lesovoy, V.
Lipatov, O.
Tomczak, P.
Lyulko, O.
Alyasova, A.
Harza, M.
Kogan, M.
Alexeev, B. Y.
Sternberg, C. N.
Szczylik, C.
Zhang, J.
Strahs, A.
Esteves, B.
Slichenmyer, W.
Berkenblit, A.
Hutson, T. E.
BJU INTERNATIONAL, 2012, 110 : 14 - 14
[47] A multicenter, open-label phase II trial of secondline apatinib plus irinotecan in patients with advanced gastric cancer
Peng, Jianjun
Li, Yong
Xiao, Jianjun
Liu, Huaqiang
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[48] A phase 2, randomized, open-label, multicenter study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC.
Li, Jingjing
Qi, Xu
Wei, Qing
Han, Zhe
Cong, Luo
Zhang, Fabiao
Ying, Jieer
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[49] APACT: Phase III, Multicenter, International, Open-Label, Randomized Trial of Adjuvant nab-Paclitaxel Plus Gemcitabine (nab-P/G) Versus Gemcitabine (G) for Surgically Resected Pancreatic Adenocarcinoma
Ko, A.
Reni, M.
Riess, H.
Pelzer, U.
O'Reilly, E. M.
Winter, J.
Oh, D. Y.
Li, C. P.
Tortora, G.
Chang, H. M.
Lopez, C. D.
Tabernero, J.
Van Cutsem, E.
Philip, P.
Goldstein, D.
Berlin, J. D.
Ferrara, S.
Li, M.
Lu, B.
Romano, A.
Marks, H.
Biankin, A.
Tempero, M. A.
PANCREAS, 2019, 48 (10) : 1464 - 1464
[50] A multicenter, open-label, phase I study of nivolumab alone or in combination with gemcitabine plus cisplatin in patients with unresectable or recurrent biliary tract cancer.
Ikeda, Masafumi
Ueno, Makoto
Morizane, Chigusa
Kobayashi, Satoshi
Ohno, Izumi
Kondo, Shunsuke
Okano, Naohiro
Kimura, Keisuke
Asada, Suguru
Namba, Yoshinobu
Okusaka, Takuji
Furuse, Junji
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)

← 1 2 3 4 5 →